Puretech Health operating losses narrow in 'landmark year'
Biotechnology company said on Thursday that 2023 had been "a landmark year" for the group, making "strong strategic and clinical progress".
Puretech Health said total revenues had fallen from $15.61m in FY22 to $3.33m in FY23 but also noted that operating losses had narrowed to $146.99m from $197.8m, general and administrative expenses had dropped from $60.99m to $53.29m, and research and development expenses fell from $152.44m to $96.23m.
Pre-tax losses also narrowed, improving from a loss of $92.78m in FY22 to $36.1m in FY23. On a per share basis, however, Puretech reported a loss per share of 0.24p, widening from FY22's 0.18p loss.
The FTSE 250-listed firm added that its level cash, cash equivalents and short-term investments were $326.0m at he end of the year, while its consolidated cash, cash equivalents and short-term investments were $327.1m and said it has operational runway into "at least 2027".
Chief executive Bharatt Chowrira said: "2023 was a landmark year for PureTech, in which we made strong strategic and clinical progress. We've carried this momentum into 2024, with our hub-and-spoke R&D model continuing to deliver value for both patients and shareholders. Through this model we are able to ambitiously pursue our mission of giving life to science by developing therapies that make a meaningful difference to patients with devastating diseases."
As of 1005 BST, Puretech shares were up 5.18% at 223.50p.
Reporting by Iain Gilbert at Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.